Cover Image


Research on China Monoclonal Antibody (McAB) Industry, 2014

出版商 Huidian Research 商品編碼 310740
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
Back to Top
中國的單株抗體(McAB)產業 Research on China Monoclonal Antibody (McAB) Industry, 2014
出版日期: 2014年07月01日 內容資訊: 英文 60 Pages



第1章 單株抗體概要

  • 定義與特徵
  • 單株抗體的製作過程
  • 分類
  • 作用機制
  • 主要的技術

第2章 中國的單株抗體產業的商業環境

  • 經濟環境分析
  • 政策分析

第3章 全球單株抗體產業現狀與趨勢

  • 全球單株抗體市場發展歷史
  • 上市的單株抗體
  • 致力於開發單株抗體的全球主要企業
  • 全球抗體市場的強力成長
  • 開發趨勢與全球單株抗體預測

第4章 中國的單株抗體產業的產業情形

  • 小市場規模
  • 單株抗體的上市情形
  • 中國和海外各國的研究進展比較
  • 單株抗體的最初高峰

第5章 中國的主要單株抗體企業

  • Shanghai CP Guojian Pharmaceutical Co., Ltd.(CPGJ)
  • Biotech Pharmaceuticals Co., Ltd.
  • Chengdu Huasun Biotechnology Co., Ltd.
  • Zhejiang HISUN Pharmaceutical Co., Ltd.
  • Shanghai Bio Pharmaceutical Co., Ltd.

第6章 今後中國的單株抗體市場具有大的成長可能性與發展機會

  • 巨大的中國市場發展空間與潛在的醫療需求
  • 後發優勢與中國單株抗體市場特有的機會

Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on policy environment, global market, Chinese market, as well as the latest developments of domestic key enterprises related to China's monoclonal antibody industry.

Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and development of monoclonal antibody agents, which have achieved results in 2013. Hengrui Medicine Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and Qilu Pharm have applied for clinical research of monoclonal antibody agents. And Walvax Biotechnology Co., Ltd even made a huge investment in purchasing Genor Biopharma Co., Ltd, attempting to establish a large biological strategy. Although large-scale pharmaceutical enterprises entered monoclonal antibody field on a large scale, the overall innovation is still insufficient, and the market is represented by monoclonal antibody agents and biological analogue that have submitted applications, few imitated drugs, and innovative medicines are rare and precious things, mainly on account of high risks and long-time cycle.

Due to late state, China's strength on research and development will be still vulnerable within future three to five years, so it has to open the market preliminarily by depending on generic drugs. In 2013, the market size was CNY 3.8 billion around, up 30% year-on-year; product categories and sales volume were far less than that of European and American countries.

According to statistical data of Shanghai Pharmaceutical Profession Association (SPPA), China will see four to six monoclonal antibody agents by 2016, such as Trastuzumab and Rituximab. And it is expected by 2020, six to ten monoclonal antibody agents will be listed in market, and some of which are independently researched drugs. Huidian Research believes that China's monoclonal antibody market will embrace its first climax from 2017 to 2020.

Table of Contents

1. Overview of Monoclonal Antibody

  • 1.1. Definition and Characteristics
  • 1.2. Preparation Process of Monoclonal Antibody
  • 1.3. Classification
  • 1.4. Mechanism of Action
  • 1.5. Key Technology

2. Operation Environment of China's Monoclonal Antibody Industry

  • 2.1. Analysis of Economic Environment
  • 2.2. Policy Analysis
    • 2.2.1. Monoclonal Antibody Industry Ranks as a Strategic Emerging Industry
    • 2.2.2. NCCN Guidance Supports Monoclonal Antibody Agents; McAB Agents are Included into Local Health Insurance

3. Current Situation and Tendencies of Worldwide Monoclonal Antibody Industry

  • 3.1. Development History Overview of International Monoclonal Antibody Market
  • 3.2. Monoclonal Antibody Agents Listing in Market
  • 3.3. Global Key Enterprises Devoting to Developing Monoclonal Antibody Agents
  • 3.4. Powerful Growth Momentum of Global Antibody Market
  • 3.5. Development Tendency and Outlook of Global Monoclonal Antibody Agents
    • 3.5.1. Develop Monoclonal Antibody Aiming at New Target Spots
    • 3.5.2. Diversified Research and Development on Monoclonal Antibody
    • 3.5.3. Antibody-Drug-Conjugates (ADCs) as a New Research Hotspot and Development Direction
    • 3.5.4. First Monoclonal Antibody Biological Analogue Approved in European and American Market

4. Operation Situation of China's Monoclonal Antibody Industry

  • 4.1. Small Market Size
  • 4.2. Listing Situation of Monoclonal Antibody Agents
  • 4.3. Comparison of Research Progress between China and Foreign Countries
    • 4.3.1. China's Research Progress on Monoclonal Antibody
    • 4.3.2. Differences of New R& D Ability and Industrialization between China and Foreign Countries
  • 4.4. The First Climax of Monoclonal Antibody: 2017 to 2020

5. China's Key Monoclonal Antibody Agent Enterprises

  • 5.1. Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ)
    • 5.1.1. Company Profile
    • 5.1.2. Business Condition
    • 5.1.3. The Generic Drug of Trastuzumab - Sai Pu Ting Approved for Clinical Use
  • 5.2. Biotech Pharmaceuticals Co., Ltd.
    • 5.2.1. Company Profile
    • 5.2.2. Business Condition
    • 5.2.3. Production Process
  • 5.3. Chengdu Huasun Biotechnology Co., Ltd.
    • 5.3.1. Company Profile
    • 5.3.2. Representative Products
    • 5.3.3. Business Condition
  • 5.4. Zhejiang HISUN Pharmaceutical Co., Ltd.
    • 5.4.1. Company Profile
    • 5.4.2. Business Condition
    • 5.4.3. Progress of R & D
  • 5.5. Shanghai Bio Pharmaceutical Co., Ltd.
    • 5.5.1. Company Profile
    • 5.5.2. Business Condition
    • 5.5.3. Progress of R & D

6. Huge Growth Potential and Development Opportunities of China Monoclonal Antibody Market in the Future

  • 6.1. Enormous China's Market Space and Potential Medical Demand not Get Satisfied
  • 6.2. Late-Mover Advantage and Unique Opportunity of China Monoclonal Antibody Market
Back to Top